Gilbert, Mark R.
Pugh, Stephanie L.
Aldape, Ken
Sorensen, A. Gregory
Mikkelsen, Tom
Penas-Prado, Marta
Bokstein, Felix
Kwok, Young
Lee, R. Jeffrey
Mehta, Minesh
Funding for this research was provided by:
National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10 CA37422, U24CA180803)
Article History
Received: 11 May 2016
Accepted: 9 October 2016
First Online: 21 October 2016
Compliance with ethical standards
:
: Dr. Gilbert reports personal fees and non-financial support from Merck, personal fees from Genentech Roche, personal fees from Abbvie, personal fees from Wellcome Trust, and personal fees from Foundation Medicine, outside the submitted work. Dr. Sorensen reports employment by Siemens Healthcare, outside the submitted work. Dr. Mikkelsen has a consulting or advisory role with Roche Genentech and has received honoraria, travel and research funding from Roche Genentech, outside the submitted work. Dr. Penas-Prado has received research funding from Bayer, Genentech, Glaxo, and Novartis, outside the submitted work. Dr. Mehta has a leadership role with Pharmacyclics, stock or ownership interest in Pharmacyclics, consulting or advisory roles with Cavion, Elekta, Novartis and Novocure, and has received research funding from Novocure and Novellos, outside the submitted work.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.